Derm-Biome’s DB-007-5 Highly Effective in Atopic Dermatitis Study
Derm-Biome Pharmaceuticals announced positive preclinical results for its topical drug DB-007-5 in treating atopic dermatitis (AD). The drug significantly...
Sonnet BioTherapeutics Son-1010: Improved Solid Tumor Treatment
Sonnet BioTherapeutics presented data at the 2025 AACR:IO Conference on its Fully Human Albumin Binding (FHAB) platform, which enhances...
First Participant Dosed in Phase 1a Study of Oral HDV Entry Inhibitor
Assembly Biosciences has dosed the first participant in a Phase 1a clinical trial for ABI-6250, an oral HDV entry...
PDS Biotech’s HPV Cancer Data in JAMA Oncology: Positive Survival, Clinical Responses
PDS Biotechnology Corporation announced promising clinical trial results for a triple combination therapy targeting HPV-associated cancers, published in JAMA...
Pyx-201 Gets FDA Fast Track for Head & Neck Cancer
Pyxis Oncology’s PYX-201, an antibody-drug conjugate targeting Extradomain-B Fibronectin (EDB+FN), received Fast Track Designation from the FDA for treating...
Lucid-21-302 Phase 1 Trial Complete: Quantum Biopharma’s MS Drug Shows Promise
Quantum BioPharma Ltd. announced the successful completion of a Phase 1 clinical trial for Lucid-MS, a novel neuroprotective compound...
Plus Therapeutics Rhenium-186 Obisbemeda: A Promising Therapeutic for Leptomeningeal Metastases
Plus Therapeutics completed its Phase 1 single-dose escalation trial of Rhenium (¹⁸⁶Re) Obisbemeda, administered intrathecally, for patients with leptomeningeal...
FDA Accepts Regeneron Odronextamab Resubmission for Follicular Lymphoma Review
Regeneron Pharmaceuticals announced that the FDA accepted its resubmitted Biologics License Application (BLA) for odronextamab. The drug is intended...
Emalex Biosciences Tourette Syndrome Study Meets Endpoints
Emalex Biosciences’ Phase 3 trial of ecopipam, a dopamine-1 receptor antagonist, demonstrated statistically significant improvement in Tourette syndrome symptoms...
TNF Pharmaceuticals Launches Phase 2b Trial of Oral TNF Inhibitor
TNF Pharmaceuticals has initiated a fully funded Phase 2b clinical trial for isomyosamine, an oral TNF-α inhibitor, targeting muscle...